Current Issue
–ABOUT THE COVER–
Monoclonal antibodies have revolutionized the treatment of allergic diseases by selectively targeting key immune mediators. This scientific illustration depicts the main biological therapies used in allergic conditions and their mechanisms of action. Omalizumab inhibits IgE, reducing the activation of mast cells and basophils. Dupilumab blocks IL-4Rα and IL-13, modulating the Th2 response. Mepolizumab and Reslizumab act on IL-5, preventing eosinophilic inflammation, while Benralizumab inhibits IL-5Rα, reducing eosinophil levels. Tezepelumab blocks TSLP, a key regulator of allergic inflammation. Although these therapies enhance disease control, their increasing use has led to a higher incidence of adverse drug reactions (ADRs), which are classified as pharmacologic (type A) or immunologic (type B). Understanding the mechanisms involved in these reactions is crucial to optimizing their clinical use. This review provides an up-to-date synthesis on the use of monoclonal antibodies in allergic diseases, offering a comprehensive overview of their applications in the medical field.
Cover illustration by: Dr. Rosalaura Virginia Villarreal González.
Special thanks for the image acquisition (Villarreal-González RV, et al.) and editing of the cover: DG. Diana Gabriela Salazar Rodríguez.